JAMA
JAMA
Audio Summaries
Every issue of JAMA moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
JAMA covers research in these specialties.
Recent summaries
The latest articles summarized from JAMA.
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026
The study aimed to determine whether digoxin improves outcomes related to death or worsening heart failure in patients with symptomatic rheumatic heart disease compared to a placebo. The results indicated that digoxin significantly reduced the risk of the composite outcome of all-cause death or new-onset/worsening heart failure, with a low incidence of toxicity. Overall, digoxin appears to be a beneficial treatment option for this patient population.
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026
The authors aimed to evaluate the efficacy and safety of digitalis glycosides in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or reduced ejection fraction (HFrEF). Their meta-analysis of three randomized controlled trials involving 9,013 patients found that digitalis glycosides significantly reduced the risk of cardiovascular death or first worsening heart failure event, primarily by lowering the incidence of worsening heart failure. These findings suggest that digitalis glycosides may be a beneficial adjunct therapy for managing these heart failure conditions.
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial
May 8, 2026
The TNK-PLUS randomized clinical trial aimed to determine whether administering intravenous tenecteplase prior to endovascular treatment (EVT) improves functional outcomes in patients with ischemic stroke due to proximal middle cerebral artery occlusion, occurring 4.5 to 24 hours after symptom onset. The study found no significant difference in functional independence at 90 days between patients receiving tenecteplase before EVT and those receiving EVT alone, suggesting that tenecteplase does not enhance clinical outcomes in this late treatment window. Additionally, the rates of mortality and symptomatic intracranial hemorrhage were comparable between the two groups.
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial
May 8, 2026
The INSTANT trial aimed to evaluate the efficacy and safety of intravenous tirofiban in patients with acute ischemic stroke who did not respond adequately to intravenous tenecteplase and lacked large or medium vessel occlusions or cardioembolic sources. The results indicated that adjunctive tirofiban significantly improved the likelihood of achieving an excellent outcome at 90 days compared to placebo, with a low incidence of symptomatic intracranial hemorrhage and mortality.
Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial
May 7, 2026
The CHOICE-2 randomized clinical trial aimed to determine whether adjunctive intra-arterial alteplase after successful thrombectomy improves functional outcomes and cerebral reperfusion in patients with acute ischemic stroke due to large vessel occlusion. The results indicated that the combination treatment significantly increased the proportion of patients achieving an excellent functional outcome at 90 days compared to thrombectomy alone, although it was associated with higher mortality rates, necessitating further investigation.
Changes in Nonprofit Hospitals' Finances, Operations, and Quality of Care After Using Management Consultants
May 4, 2026
The authors aimed to quantify the spending of nonprofit hospitals on management consultants and assess the subsequent impacts on their finances, operations, and quality of care. Despite over $7.8 billion spent on consulting services from 2009 to 2023, the study found little evidence of significant improvements in these areas, raising concerns about the effectiveness and value of management consulting in the nonprofit hospital sector.
Hepatitis B: A Review
May 4, 2026
This review examines the global impact of hepatitis B virus (HBV) infection, which affects approximately 254 million people and leads to about 1.1 million deaths annually. The authors aim to highlight effective prevention strategies, such as universal birth-dose vaccination and antiviral therapies, which significantly reduce perinatal transmission and the progression of chronic HBV infection to severe liver complications. The findings underscore the importance of vaccination and timely treatment in mitigating the health burden of HBV.
Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial
Apr 30, 2026
The authors aimed to determine whether adjunctive embolization of the middle meningeal artery (EMMA) reduces the recurrence of chronic subdural hematomas compared to surgical drainage alone. The randomized clinical trial found that EMMA significantly decreased the rate of symptomatic recurrence at 90 days, with only 4.3% of patients in the EMMA group experiencing recurrence compared to 28% in the control group. These results suggest that EMMA may be an effective strategy to improve outcomes for patients undergoing surgery for chronic subdural hematomas.
The Veteran Affairs' Whole Health Approach for Chronic Pain Management: The wHOPE Randomized Clinical Trial
Apr 29, 2026
The study aimed to evaluate the effectiveness of the Veteran Affairs' Whole Health team intervention for managing chronic pain in comparison to cognitive behavioral therapy (CBT) and usual care. Results indicated that the Whole Health approach led to a statistically significant reduction in pain interference scores after 12 months, outperforming both CBT and usual care, while CBT did not show significant advantages over usual care. These findings suggest that the Whole Health model may be a beneficial strategy for chronic pain management in VA patients.
Cardiac Resynchronization Therapy: A Review
Apr 27, 2026
This review examines the role of cardiac resynchronization therapy (CRT) in managing heart failure (HF) associated with cardiac dyssynchrony, particularly in patients with left ventricular (LV) systolic dysfunction and left bundle-branch block. The authors highlight the benefits of CRT, including improved LV function, reduced hospitalization rates for HF, and lower mortality compared to standard medical therapy. They emphasize the importance of timely referral for CRT to optimize clinical outcomes in this patient population.